EDROPHONIUM
Because it lacks a carbamate group,
edrophonium must rely on noncovalent bonding to the acetyl-cholinesterase
enzyme. The quaternary ammonium group limits lipid solubility.
Edrophonium is less than 10% as potent
as neostig-mine. The recommended dosage is 0.5–1 mg/kg. Edrophonium is
available as a solution containing 10 mg/mL; it is available with atropine as a
combi-nation drug (Enlon-Plus; 10 mg edrophonium and 0.14 mg atropine per mL).
Edrophonium has the most rapid onset of
action (1–2 min) and the shortest duration of effect of any of the
cholinesterase inhibitors. Reduced doses should not be used, because
longer-acting muscle relaxants may outlast the effects of edrophonium. Higher
doses prolong the duration of action to more than 1 hr. Edrophonium may not be
as effective as neostigmine at reversing intense neuromuscular blockade. In
equipotent doses, muscarinic effects of edrophonium are less pronounced than
those of neostigmine or pyridostigmine, requiring only half the amount of
anticholinergic agent. Edrophonium’s rapid onset is well matched to that of
atropine (0.014 mg of atropine per 1 mg of edrophonium). Although
glycopyrrolate (0.007 mg per 1 mg of edrophonium) can also be used, it should
be given several minutes prior to edrophonium to avoid the possibility of
bradycardia.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.